Combining the mTORC1/2 inhibitor #onatasertib with the #PD1antibody #toripalimab offers a manageable safety profile and promising efficacy in advanced #SolidTumors—especially recurrent or #MetastaticCervicalCancer—regardless of #PDL1 expression.

#STTT: doi.org/10.1038/s413...

Adding the #PD1antibody #tislelizumab to perioperative SOX #chemotherapy in locally advanced #GastroesophagealJunctionAdenocarcinoma achieved high pathological response & R0 resection rates with manageable safety, supporting its therapeutic potential.

#STTT: doi.org/10.1038/s413...